Spanish company Genosa, the University and Hospital of Jaén will carry out a clinical study of a dietary supplement called Mygrium
The double-blind study and placebo controlled study will evaluate a specific combination of olive polyphenols, including hydroxytyrosol oleuropein, tyrosol, verbascosides and others, together with vitamins B1, B2, B3, B6 and C against fibromyalgia symptoms.
Fibromyalgia is a chronic and complex disease that presents with generalised musculoskeletal pain accompanied by strong joint stiffness, poor night's rest and a state of generalised fatigue, which causes significant limitations in people who suffer from it.
Researchers in the Cell Biology Area of the University of Jaén (UJA) and coordinator of the study, Dr Ma Luisa del Moral Leal, explains that the research group 'Cellular Stress and Age' at the University of Jaén has been working for a long time in the line of research 'Fibromyalgia and olive oil ', counting on the collaboration of AFIXA, whose management and members are grateful for their involvement.
In this sense, the UJA research group has published several studies that show that the consumption of extra virgin olive oil, and specifically one of its phenolic compounds, hydroxytyrosol, provides protection in terms of oxidative homeostatic balance and reduction of inflammation, as well as changes in the dermal fibroblast proteome of fibromyalgia patients, concluding that it could be highly beneficial in the management of fibromyalgia.
This study takes a further step in the line of research initiated by the UJA, analysing, among other aspects, the possible changes in the plasma proteome after the administration of Mygrium in people affected by fibromyalgia.
Dr Esther Ocaña, head of the Clinical Management Unit of the Laboratory of the Hospital Universitario de Jaén, points out that “the results of the different analytical parameters will be determined in our laboratory will measure the inflammatory state, liver and kidney function and metabolism of carbohydrates. This will help us to know the effect of this product on the clinical evolution of patients”.
Carlos Peña, Genosa CEO, Genosa has participated in the design of the study and the formulation of such combination of olive polyphenols. He indicates that “2021 is our 20th aniversary. During all these years we have been contributing to get healthy values from olive source and help people with their daily limitations”.
Andrés Garrido, CEO of the technology-based company Solvitae Medical, states that "Mygrium is already being used for diminishing the number of migraine episodes. After some cases of patients with multiple sclerosis and fibromyalgia and also the clinicals published by Dr. del Moral and her team, we decided to move forward with a new clinical about fibromyalgia”.
Ana Colmenero from AFIXA states that “there are already many research studies in which AFIXA has actively participated with the sole objective and interest of supporting each initiative that they offer us. Thanks to the University of Jaén, the University Hospital of Jaén and the Solvitae Medical company, for the effort and dedication in this study. Go ahead, the sick are the first interested in advancing the research and that is the only reason why we selflessly lend our body, our time and our dreams”.
R.M. Málaga, hoja 51.899-1, folio 143, tomo 2.895, libro 1.808, sección 8a. CIF: B-92284512